Company intelligence / Profile preview
Resolve Therapeutics
Miami, Florida, USAresolvetherapeutics.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Phase 2
01
Overview
Resolve’s lead candidate RSLV‑132 has completed three clinical trials demonstrating safety and symptom improvement in SLE, Sjogren’s syndrome, and long COVID. The company continues to pursue additional indications with high unmet need where nucleic acids drive disease pathology[1].
- Therapeutic areas
- PulmonologyCardiovascularImmunologyDermatologyHematologyNeurologyInfectious Diseases
- Modalities
- Nuclease Fc fusion proteins (biologic drugs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Technology licensed from University of Washingtonplans to partner with pharmaceutical companies for late-stage development/commercialization[4]
Beyond the preview
Go deeper on Resolve Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Resolve Therapeutics.